MDT MDT

Name: MDT Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored April 20, 2026

Price at analysis: $86.19

Crucible Score

63.5

B-

Quality × Value Composite

KQI — Quality

68.1

Fundamental Quality Index

KVI — Value

57.8

Valuation Attractiveness Index

Crucible Verdict — MDT

Medtronic scores a solid B- on financial quality and diversification strength, but growth remains the clear weakness at just 57 points despite CEO Geoff Martha's strong execution track record. MDT trades at a 7% discount to fair value, creating a reasonable entry point for investors willing to accept modest growth in exchange for stability. The earnings consistency suggests defensive appeal in uncertain markets.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality

72.7

Growth Profile

57.1

Moat Durability

66.7

Management Effectiveness

68.0

Diversification & Resilience⚠

76.0

Market Position

68.0

Weakest dimension: Growth Profile (57.1)

◆ KVI Value Dimensions

DCF Margin of Safety

63.6

FCF Yield & Cash Returns

53.2

Relative Valuation

77.4

Growth-Adjusted Value

17.2

Historical Valuation

79.3

Macro Context

58.4

◆ DCF Valuation Scenarios

Bear Case

$68.42

Base Case

$92.57

Bull Case

$124.83

Price at Analysis

$86.19

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$68.42	2.5%	16.0%	8.9%
🟢 Base	$92.57	4.0%	18.0%	8.4%
🟢 Bull	$124.83	5.5%	20.0%	7.9%

Key Assumptions: Revenue growth anchored to historical ~2-4% organic growth with MDT's mature med-device portfolio; operating margins range from 16% (bear, reflecting pricing pressure and tariff headwinds) to 20% (bull, reflecting mix shift to higher-margin robotic surgery and diabetes platforms). WACC derived from CAPM using 0.76 beta with 5.5% ERP for base, adjusted +/-50bps for bear/bull; tax rate normalized at 17% reflecting MDT's Irish domicile advantage. D&A-to-capex convergence assumed over projection period with capex at ~5% of revenue.

◆ Financial Snapshot

Profitability

Gross Margin61.9%

Operating Margin17.9%

Net Margin13.0%

ROIC6.5%

ROE9.4%

Balance Sheet

Balance SheetD/E: 0.57*, CR: 2.54* (* = TTM)

Cash ConversionFCF/EPS: 1.17x

Capital IntensityCapex/Rev: 5.5%

Altman Z-Score2.87 (Grey)

Piotroski F-Score7/9 (Good)

Growth

Revenue CAGR2.7% CAGR

Earnings CAGR6.6% CAGR

Growth ConsistencyCV: 1.80

Segment Breadth3/4 growing (75%)

Quarterly TrendMargin↑, Exp↓

Earnings CredibilityConsistent Beater

◆ Analyst Consensus & Leadership

Leadership & Governance

CEOGeoff Martha · 8 years

CEO Ownership< 1%

Compensation87% performance-based

Insider ActivityBuying

Capital AllocationROIC 6.5% vs WACC 2.0%

Earnings Beat Rate97% (21/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted April 20, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.